Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.40 |
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | CA9 | Q16790 | 3/20 | 0.40 |
| ▸ | P4HB | P07237 | 1/20 | 0.40 |
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.40 |
| ▸ | LPL | P06858 | 6/20 | 0.40 |
| ▸ | F11 | P03951 | 3/20 | 0.40 |
| ▸ | F2 | P00734 | 2/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.40 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.40 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.39 |
| ▸ | MLYCD | O95822 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22858738 | 0.84 | FFAR1 (0.39) | FFAR1CA1CA2CA9P4HB | |
| SCHEMBL22922489 | 0.81 | HDAC4 (0.43) | CA1CA2CA9P4HBLIPG | |
| SCHEMBL28506151 | 0.81 | HDAC4 (0.43) | CA1CA2CA9P4HBLIPG | |
| SCHEMBL1290961 | 0.79 | P4HB (0.48) | CA1CA2CA9P4HBLIPG | |
| SCHEMBL22858794 | 0.78 | P4HB (0.43) | CA1CA2CA9P4HBLIPG | |
| SCHEMBL22858980 | 0.78 | P4HB (0.43) | CA1CA2CA9P4HBLIPG | |
| SCHEMBL22858793 | 0.78 | P4HB (0.43) | CA1CA2CA9P4HBLIPG | |
| SCHEMBL28513866 | 0.78 | LIPG (0.40) | CA1CA2CA9P4HBLIPG | |
| SCHEMBL15464280 | 0.77 | HDAC4 (0.46) | CA1CA2CA9P4HBLIPG | |
| SCHEMBL12781285 | 0.76 | LPL (0.49) | CA1CA2CA9P4HBLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12454534-B2 | Pyrrolo[2,3-b]pyrazines as HPK1 inhibitor and the use thereof | BEONE MEDICINES I GMBH (CH) | 2025-10-28 | — | — | US | disclosed |
| WO-2022253311-A1 | HPK1 INHIBITOR AND USE THEREOF | 武汉人福创新药物研发中心有限公司 | 2022-12-08 | — | — | WO | disclosed |
| WO-2022253311-A1 | HPK1 INHIBITOR AND USE THEREOF | 武汉人福创新药物研发中心有限公司 | 2022-12-08 | — | — | WO | disclosed |
| CN-115073474-A | Pyrrolo [2,3-b ] pyrazines as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2022-09-20 | — | — | CN | disclosed |
| CN-115028639-A | Pyrrolo [2,3-b ] pyrazines as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2022-09-09 | — | — | CN | disclosed |
| US-20220267333-A1 | PYRROLO[2,3-b]PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF | BEONE MEDICINES I GMBH (CH) | 2022-08-25 | — | — | US | disclosed |
| EP-3994136-A1 | PYRROLO [2, 3-B] PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF | BeiGene, Ltd. (KY) | 2022-05-11 | — | — | EP | disclosed |
| CN-114096536-A | Pyrrolo [2,3-b ] pyrazines as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2022-02-25 | — | — | CN | disclosed |
| CN-112243439-A | Pyrrolo [2,3-B ] pyridines or pyrrolo [2,3-B ] pyrazines as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2021-01-19 | — | — | CN | disclosed |
| WO-2021000925-A1 | PYRROLO [2, 3-b] PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF | BEIGENE, LTD. (KY) | 2021-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220267333-A1 | PYRROLO[2,3-b]PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF | PDXK, STK25, STK35 | FFAR1 2682/4885CA1 4401/4885CA2 3455/4885 |
| US-12454534-B2 | Pyrrolo[2,3-b]pyrazines as HPK1 inhibitor and the use thereof | PDXK, STK25, STK35 | FFAR1 2682/4885CA1 4401/4885CA2 3455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.